Inhalable dry powders of rifampicin highlighting potential and drawbacks in formulation development for experimental tuberculosis aerosol therapy

References

• Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. nature. 1998;396:537–544.
   Web of Science ®Google Scholar
• Tattevin P, Casalino E, Fleury L, et al. The validity of medical history, classic symptoms, and chest radiographs in predicting pulmonary tuberculosis. Chest. 1999;115(5):1248–1253.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global tuberculosis report 2019. Geneva; 2019.
   Google Scholar
• Nahid P, Dorman SE, Alipanah N, et al. Executive summary: official American thoracic society/centers for disease control and prevention/infectious diseases society of america clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):853–867.
   PubMed Web of Science ®Google Scholar
• Guirado E, Schlesinger LS. Modeling the Mycobacterium tuberculosis Granuloma – the critical battlefield in host immunity and disease. Front Immunol. 2013;4:1–7.
   PubMed Web of Science ®Google Scholar
• Dartois V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat Rev Microbiol. 2014;12(3):159–167.
   PubMed Web of Science ®Google Scholar
• Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications: physiological factors affecting the effectiveness of inhaled drugs. Br J Clin Pharmacol. 2003;56(6):588–599.
   PubMed Web of Science ®Google Scholar
• Lee W-H, Loo C-Y, Traini D, et al. Inhalation of nanoparticle-based drug for lung cancer treatment: advantages and challenges. Asian J Pharm Sci. 2015;10(6):481–489.
   Web of Science ®Google Scholar
• Newman SP. Principles of metered-dose inhaler design. Respir CARE. 2005;50(9):1177–1190.
   PubMedGoogle Scholar
• Berkenfeld K, Lamprecht A, McConville JT. Devices for dry powder drug delivery to the lung. AAPS PharmSciTech. 2015;12:479–490.
   Google Scholar
• Khadka P, Dummer J, Hill PC, et al. Considerations in preparing for clinical studies of inhaled rifampicin to enhance tuberculosis treatment. Int J Pharm. 2018;548(1):244–254.
   PubMedGoogle Scholar
• Maggi N, Pasqualucci CR, Ballotta R, et al. Rifampicin: a new orally active rifamycin. Chemotherapy. 1966;11(5):285–292.
   PubMed Web of Science ®Google Scholar
• Henwood SQ, Liebenberg W, Tiedt LR, et al. Characterization of the solubility and dissolution properties of several new rifampicin polymorphs, solvates, and hydrates. Drug Dev Ind Pharm. 2001;27(10):1017–1030.
   PubMed Web of Science ®Google Scholar
• Son Y-J, McConville JT. A new respirable form of rifampicin. Eur J Pharm Biopharm. 2011;78(3):366–376.
   PubMed Web of Science ®Google Scholar
• Li J Supramolecular modification of selected antitubercular drugs. Inaugural Dissertation. Cape town. (2010).
   Google Scholar
• Gadret M, Goursolle M, Leger JM, et al. Structure cristalline de la rifampicine C43N4O12H58.5H2O. Acta Crystallogr B. 1975;31(5):1454–1462.
   Google Scholar
• de Villiers MM, Caira MR, Li J, et al. Crystallization of toxic glycol solvates of rifampin from glycerin and propylene glycol contaminated with ethylene glycol or diethylene glycol. Mol Pharm. 2011;8(3):877–888.
   PubMedGoogle Scholar
• Wicher B, Pyta K, Przybylski P, et al. Solvates of zwitterionic rifampicin: recurring packing motifs via nonspecific interactions. Cryst Growth Des. 2018;18(2):742–754.
   Web of Science ®Google Scholar
• Pelizza G, Nebuloni M, Ferrari P. et al. Polymorphism of rifampicin. Il Farmaco. 1977;32(7):471–480.
   PubMedGoogle Scholar
• Loos U, Musch E, Jensen JC, et al. Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin Wochenschr. 1985;63(23):1205–1211.
   PubMedGoogle Scholar
• Niemi M, Backman JT, Fromm MF, et al. Pharmacokinetic interactions with rifampicin. Clin Pharmacokinet. 2003;42(9):819–850.
   PubMed Web of Science ®Google Scholar
• Boeree MJ, Diacon AH, Dawson R, et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med. 2015;191(9):1058–1065.
   PubMed Web of Science ®Google Scholar
• Boeree MJ, Heinrich N, Aarnoutse R, et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2017;17(1):39–49.
   PubMed Web of Science ®Google Scholar
• Peloquin CA, Velásquez GE, Lecca L, et al. Pharmacokinetic evidence from the HIRIF trial to support increased doses of rifampin for tuberculosis. Antimicrob Agents Chemother. 2017;61(8):e00038–17.
   PubMed Web of Science ®Google Scholar
• Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf. 2006;5(2):231–249.
   PubMed Web of Science ®Google Scholar
• Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet. 2001;40(5):327–341.
   PubMed Web of Science ®Google Scholar
• Page KR, Sifakis F, de Oca RM, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med. 2006;166(17):1863–1870.
   PubMedGoogle Scholar
• Watson RO, Manzanillo PS, Cox JS, et al. tuberculosis DNA targets bacteria for autophagy by activating the host DNA-sensing pathway. Cell. 2012;150(4):803–815.
   PubMed Web of Science ®Google Scholar
• Hoppentocht M, Hagedoorn P, Frijlink HW, et al. Developments and strategies for inhaled antibiotic drugs in tuberculosis therapy: a critical evaluation. Eur J Pharm Biopharm. 2014;86(1):23–30.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–269.
   PubMed Web of Science ®Google Scholar
• Changsan N, Chan H-K, Separovic F, et al. Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation. J Pharm Sci. 2009;98(2):628–639.
   PubMed Web of Science ®Google Scholar
• Changsan N, Nilkaeo A, Pungrassami P, et al. Monitoring safety of liposomes containing rifampicin on respiratory cell lines and in vitro efficacy against Mycobacterium bovis in alveolar macrophages. J Drug Target. 2009;17(10):751–762.
   PubMed Web of Science ®Google Scholar
• Kumar GSV, Varghese M, Annapoorna A, et al. Dry powder cationic lipopolymeric nanomicelle inhalation for targeted delivery of antitubercular drug to alveolar macrophage. Int J Nanomedicine. 2013;8:2871–2885.
   PubMedGoogle Scholar
• Patil J, Devi V, Devi K, et al. A novel approach for lung delivery of rifampicin-loaded liposomes in dry powder form for the treatment of tuberculosis. Lung India. 2015;32(4):331–338.
   PubMed Web of Science ®Google Scholar
• Singh C, Koduri LVSK, Dhawale V, et al. Potential of aerosolized rifampicin lipospheres for modulation of pulmonary pharmacokinetics and bio-distribution. Int J Pharm. 2015;495(2):627–632.
   PubMedGoogle Scholar
• Rawal T, Parmar R, Tyagi RK, et al. Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis. Colloids Surf B Biointerfaces. 2017;154:321–330.
   PubMed Web of Science ®Google Scholar
• Vadakkan MV, Binil Raj SS, Kartha CC, et al. Cationic, amphiphilic dextran nanomicellar clusters as an excipient for dry powder inhaler formulation. Acta Biomater. 2015;23:172–188.
   PubMed Web of Science ®Google Scholar
• Goyal AK, Garg T, Rath G, et al. Development and Characterization of nanoembedded microparticles for pulmonary delivery of antitubercular drugs against experimental tuberculosis. Mol Pharm. 2015;12(11):3839–3850.
   PubMed Web of Science ®Google Scholar
• Goyal AK, Garg T, Rath G, et al. Chemotherapeutic evaluation of guar gum coated chitosan nanoparticle against experimental tuberculosis. J Biomed Nanotechnol. 2016;12(3):450–463.
   PubMed Web of Science ®Google Scholar
• Garg T, Rath G, Goyal AK. Inhalable chitosan nanoparticles as antitubercular drug carriers for an effective treatment of tuberculosis. Artif Cells Nanomed Biotechnol. 2016;44(3):997–1001.
   PubMed Web of Science ®Google Scholar
• Parikh R, Patel L, Dalwadi S. Microparticles of rifampicin: comparison of pulmonary route with oral route for drug uptake by alveolar macrophages, phagocytosis activity and toxicity study in albino rats. Drug Deliv. 2014;21(6):406–411.
   PubMed Web of Science ®Google Scholar
• Thorpe M. Delivery characteristics and patients; handling of two single-dose dry-powder inhalers used in COPD. Int J Chron Obstruct Pulmon Dis. 2011;6:353–363.
   PubMed Web of Science ®Google Scholar
• Mohammed H, Arp J, Chambers F, et al. Investigation of Dry Powder Inhaler (DPI) resistance and aerosol dispersion timing on emitted aerosol aerodynamic particle sizing by multistage cascade impactor when sampled volume is reduced from compendial value of 4 L. AAPS PharmSciTech. 2014;15(5):1126–1137.
   PubMed Web of Science ®Google Scholar
• Magni P. Single-dose inhalers for capsules: a consolidated tradition with ample growth prospects. Open Drug Delivery. 2012;37:26–27.
   Google Scholar
• Cipla. Cipla product brochure. [ cited 2018 May 15]. Available from: www.ciplamed.com
   Google Scholar
• Bell JH, Hartley PS, Cox JSG. Dry powder aerosols I: a new powder inhalation device. J Pharm Sci. 1971;60(10):1559–1564.
   PubMed Web of Science ®Google Scholar
• Schiavone H, Palakodaty S, Clark A, et al. Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers. Int J Pharm. 2004;281(1–2):55–66.
   PubMed Web of Science ®Google Scholar
• Parumasivam T, Chang RYK, Abdelghany S, et al. Dry powder inhalable formulations for anti-tubercular therapy. Adv Drug Deliv Rev. 2016;102:83–101.
   PubMed Web of Science ®Google Scholar
• Astete CE, Sabliov CM. Synthesis and characterization of PLGA nanoparticles. J Biomater Sci Polym Ed. 2006;17(3):247–289.
   PubMed Web of Science ®Google Scholar
• Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997;28:5–24.
   PubMed Web of Science ®Google Scholar
• Pathak Y, Thassu D. Drug delivery nanoparticles formulation and characterization. New York (NY): Informa Healthcare; 2009.
   Google Scholar
• Sethuraman VV, Hickey AJ. Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug. AAPS PharmSciTech. 2002;3(4):7–16.
   Google Scholar
• Coowanitwong I, Arya V, Kulvanich P, et al. Slow release formulations of inhaled rifampin. AAPS J. 2008;10(2):342–348.
   PubMed Web of Science ®Google Scholar
• Sung JC, Padilla DJ, Garcia-Contreras L, et al. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res. 2009;26(8):1847–1855.
   PubMed Web of Science ®Google Scholar
• Ohashi K, Kabasawa T, Ozeki T, et al. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. J Control Release. 2009;135(1):19–24.
   PubMed Web of Science ®Google Scholar
• Son Y-J, McConville JT. Preparation of sustained release rifampicin microparticles for inhalation: sustained-release inhaled rifampicin. J Pharm Pharmacol. 2012;64(9):1291–1302.
   PubMed Web of Science ®Google Scholar
• Rowe RC, Sheskey PJ, Owen SC, editors. Handbook of pharmaceutical excipients. London; Greyslake, IL; Washington, DC: Pharmaceutical Press;American Pharmacists Association; 2006.
   Google Scholar
• Kundawala A. Preparation, in vitro characterization, and in vivo pharmacokinetic evaluation of respirable porous microparticles containing rifampicin. Sci Pharm. 2014;82(3):665–681.
   PubMedGoogle Scholar
• Pai RV, Jain RR, Bannalikar AS, et al. Development and evaluation of chitosan microparticles based dry powder inhalation formulations of rifampicin and rifabutin. J Aerosol Med Pulm Drug Deliv. 2016;29(2):179–195.
   PubMed Web of Science ®Google Scholar
• Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2–3):165–196.
   PubMed Web of Science ®Google Scholar
• Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. Curr Drug Deliv. 2007;4:297–305.
   PubMedGoogle Scholar
• Shah P, Bhalodia D, Shelat P. Nanoemulsion: A pharmaceutical review. Syst Rev Pharm. 2010;1(1):24–32.
   Google Scholar
• Manca ML, Valenti D, Sales OD, et al. Fabrication of polyelectrolyte multilayered vesicles as inhalable dry powder for lung administration of rifampicin. Int J Pharm. 2014;472(1–2):102–109.
   PubMedGoogle Scholar
• Maretti E, Rustichelli C, Romagnoli M, et al. Solid lipid nanoparticle assemblies (SLNas) for an anti-TB inhalation treatment - a design of experiments approach to investigate the influence of pre-freezing conditions on the powder respirability. Int J Pharm. 2016;511(1):669–679.
   PubMedGoogle Scholar
• Maretti E, Costantino L, Rustichelli C, et al. Surface engineering of solid lipid nanoparticle assemblies by methyl α- d -mannopyranoside for the active targeting to macrophages in anti-tuberculosis inhalation therapy. Int J Pharm. 2017;528(1–2):440–451.
   PubMedGoogle Scholar
• Srichana T, Ratanajamit C, Juthong S, et al. Evaluation of proinflammatory cytokines and adverse events in healthy volunteers upon inhalation of antituberculosis drugs. Biol Pharm Bull. 2016;39(11):1815–1822.
   PubMed Web of Science ®Google Scholar
• Mizoe T, Ozeki T, Okada H. Application of a four-fluid nozzle spray drier to prepare inhalable rifampicin-containing mannitol microparticles. AAPS PharmSciTech. 2008;9(3):755–761.
   PubMed Web of Science ®Google Scholar
• Mohseni M, Gilani K, Bahrami Z, et al. Preparation and in-vitro evaluation of rifampin-loaded mesoporous silica nanoaggregates by an experimental design. IJPR. 2015;14:359–371.
   Google Scholar
• Rawal T, Kremer L, Halloum I, et al. Dry-powder inhaler formulation of rifampicin: an improved targeted delivery system for alveolar tuberculosis. J Aerosol Med Pulm Drug Deliv. 2017;30(6):388–398.
   PubMed Web of Science ®Google Scholar
• Chan JGY, Chan H-K, Prestidge CA, et al. A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics. Eur J Pharm Biopharm. 2013;83(2):285–292.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Gengenbach T, Denman JA, et al. Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection. AAPS J. 2014;16(1):37–47.
   PubMed Web of Science ®Google Scholar
• Wang W, Zhou QT, Sun S-P, et al. Effects of surface composition on the aerosolisation and dissolution of inhaled antibiotic combination powders consisting of colistin and rifampicin. AAPS J. 2016;18(2):372–384.
   PubMed Web of Science ®Google Scholar
• Lee SH, Teo J, Heng D, et al. Tailored antibiotic combination powders for inhaled rotational antibiotic therapy. J Pharm Sci. 2016;105(4):1501–1512.
   PubMed Web of Science ®Google Scholar
• Momin MAM, Tucker IG, Doyle CS, et al. Co-spray drying of hygroscopic kanamycin with the hydrophobic drug rifampicin to improve the aerosolization of kanamycin powder for treating respiratory infections. Int J Pharm. 2018;541(1–2):26–36.
   PubMedGoogle Scholar
• Momin MAM, Tucker IG, Doyle CS, et al. Manipulation of spray-drying conditions to develop dry powder particles with surfaces enriched in hydrophobic material to achieve high aerosolization of a hygroscopic drug. Int J Pharm. 2018;543(1–2):318–327.
   PubMedGoogle Scholar
• Kadota K, Senda A, Tagishi H, et al. Evaluation of highly branched cyclic dextrin in inhalable particles of combined antibiotics for the pulmonary delivery of anti-tuberculosis drugs. Int J Pharm. 2017;517(1–2):8–18.
   PubMed Web of Science ®Google Scholar
• Pacheco P, White D, Sulchek T. Effects of microparticle size and Fc density on macrophage phagocytosis. PLoS ONE. 2013;8(4):e60989.
   PubMed Web of Science ®Google Scholar
• Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proc Natl Acad Sci. 2006;103(13):4930–4934.
   PubMed Web of Science ®Google Scholar
• Park JH, Oh N. Endocytosis and exocytosis of nanoparticles in mammalian cells. Int J Nanomedicine. 2014;9:51–63.
   PubMed Web of Science ®Google Scholar
• Underhill DM, Ozinsky A. Phagocytosis of microbes: complexity in Action. Annu Rev Immunol. 2002;20(1):825–852.
   PubMedGoogle Scholar
• Maretti E, Rossi T, Bondi M, et al. Inhaled solid lipid microparticles to target alveolar macrophages for tuberculosis. Int J Pharm. 2014;462(1–2):74–82.
   PubMed Web of Science ®Google Scholar
• Vergne I, Chua J, Singh SB, et al. Cell biology of Mycobacterium Tuberculosis phagosome. Annu Rev Cell Dev Biol. 2004;20(1):367–394.
   PubMedGoogle Scholar
• Kisich K, Gelperina S, Higgins M, et al. Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis. Int J Pharm. 2007;345:154–162.
   PubMed Web of Science ®Google Scholar
• Kalluru R, Fenaroli F, Westmoreland D, et al. Poly(lactide-co-glycolide)-rifampicin nanoparticles efficiently clear Mycobacterium bovis BCG infection in macrophages and remain membrane-bound in phago-lysosomes. J Cell Sci. 2013;126(14):3043–3054.
   PubMed Web of Science ®Google Scholar
• Nüsse O. Biochemistry of the phagosome: the challenge to study a transient organelle. Sci World J. 2011;11:2364–2381.
   Google Scholar
• Mor N, Simon B, Mezo N, et al. Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob Agents Chemother. 1995;39(9):2073–2077.
   PubMed Web of Science ®Google Scholar
• Crowle A, Elkins N, May M. Effectiveness of ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium, and rifampin against M. tuberculosis in cultured human macrophages. Am Rev Respir Dis. 1988;137(5):1141–1145.
   PubMedGoogle Scholar
• Darouiche RO, Hamill RJ. Antibiotic penetration of and bactericidal activity within endothelial cells. Antimicrob Agents Chemother. 1994;38(5):1059–1064.
   PubMed Web of Science ®Google Scholar
• Hand W, Corwin R, Steinberg T, et al. Uptake of antibiotics by human alveolar macrophages. Am Rev Respir Dis. 1984;129(6):933–937.
   PubMedGoogle Scholar
• Hartkoorn RC, Chandler B, Owen A, et al. Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. Tuberculosis. 2007;87(3):248–255.
   PubMed Web of Science ®Google Scholar
• Van Bambeke F. Antibiotic efflux pumps in eukaryotic cells: occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamics. J Antimicrob Chemother. 2003;51(5):1067–1077.
   PubMed Web of Science ®Google Scholar
• Suarez S, O’Hara P, Kazantseva M, et al. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm Res. 2001;18(9):1315–1319.
   PubMed Web of Science ®Google Scholar